Pharmaceuticals Sector - Solvay

110
Solvay Global Annual Report 2005
Consolidated data per share
In EUR 2002 2003 2004 2005
Capital and reserves after distribution* 32,34 32,23 34,92 45,46
Cash fl ow 12,95 9,91 12,00 15,42
REBITDA 16,69 13,16 13,88 16,13
Net income 5,59 4,78 5,92 9,51
Net income (excluding discontinued operations) 5,64 4,83 5,12 3,77
Number of shares (in thousands) at December 31 84 600 84 610 84 623 84 696
Number of shares (in thousands) for calculating IFRS
earnings per share
83 059 82 748 82 521 83 021
Diluted net income 5,58 4,78 5,90 9,46
Diluted net income (excluding discontinued
operations)
Average number of shares (in thousands) for
calculating IFRS diluted earnings per share
5,63 4,82 5,11 3,75
83 208 82 776 82 751 83 491
Gross dividend 2,40 2,40 2,53 2,67
Net dividend 1,80 1,80 1,90 2,00
Highest price 78 69,3 83,9 104,1
Lowest price 58,7 47,6 64,1 79,95
Price at December 31 65,7 68,75 81 93,1
Price/earnings at December 31 11,9 14,4 13,7 9,8
Net dividend yield 2,7% 2,6% 2,3% 2,1%
Gross dividend yield 3,7% 3,5% 3,1% 2,9%
Annual volume (thousands of shares) 25 672 27 068 27 710 44 181
Annual volume (EUR million) 1 790 1 667 2000 4011
Market capitalization at December 31 (EUR billion) 5,6 5,8 6,9 7,9
Velocity (%) 30,9 32,3 31,5 53,3
Velocity adjusted by Free Float (73%) (in%) 41,2 44,2 43 ,1 71,1